Every 10-Q that Allarity Therapeutics, Inc. (ALLR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ALLR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALLR filings page.
Allarity Therapeutics, Inc., a clinical-stage oncology company, reported continued operating losses but a strengthened cash position for the quarter and six months ended June 30, 2026. Total assets were $32.1 million, up from $18.3 million at year-end, driven mainly by cash and restricted cash of $26.9 million.
The company recorded a six‑month net loss of $6.2 million (basic and diluted loss per share $0.39) on minimal revenue of $0.025 million from DRP testing services. Operating expenses declined year over year, with research and development at $2.6 million and general and administrative at $2.7 million for the six‑month period, reflecting lower clinical and legal costs.
To fund operations, Allarity completed a $20.0 million dual‑note financing with Streeterville Capital and established a $6.0 million equity line of credit with Tumim Stone Capital. Total liabilities increased to $28.6 million, and stockholders’ equity fell to $3.5 million. Management states existing cash and restricted cash are expected to fund operations for at least twelve months from the financial statement issuance date.
Allarity Therapeutics, Inc. reported a net loss of $2.8 million for the three months ended March 31, 2026, on minimal license revenue of $0.025 million. Research and development expenses were $1.3 million and general and administrative expenses were $1.4 million, both modestly lower than a year earlier.
Cash, cash equivalents and restricted cash totaled $29.8 million as of March 31, 2026, supported by $20.0 million of new promissory notes and a $6.0 million common stock purchase agreement with Tumim Stone Capital LLC. The company repurchased 264,000 shares for $0.3 million under its share repurchase plans and believes existing capital will fund operations for at least the next twelve months while it advances its lead cancer candidate stenoparib.
Allarity Therapeutics (ALLR) filed its Q3 2025 report, highlighting a smaller quarterly net loss and stable liquidity. Net loss was $2.8 million for the quarter and $7.9 million year-to-date. Cash and cash equivalents were $16.9 million as of September 30, 2025, and management expects this to fund operations for at least the next 12 months.
Operating cash outflow was $11.6 million for the nine months. The company raised capital via an ATM program with $9.7 million net proceeds year-to-date and completed a private placement of 1,562,500 shares at $1.60 per share for roughly $2.5 million gross. Allarity also executed a share repurchase program, buying 2,600,763 shares for $2.706 million, with $2.294 million remaining authorized.
The FDA granted Fast Track designation to stenoparib for advanced ovarian cancer, supporting development interactions. The company reported a material weakness in internal controls related to accounting for the repurchase program and is implementing remediation. Shares outstanding were 16,111,461 as of September 30, 2025; 15,811,886 were reported outstanding as of November 13, 2025.
Allarity Therapeutics, Inc. reported interim results showing constrained operations but sufficient near-term liquidity. The company recorded a net loss of $5.1 million for the six months ended June 30, 2025 and negative operating cash flow of $8.2 million over the same period. Management states that $17.8 million of cash, cash equivalents and restricted cash as of June 30, 2025 is estimated to be sufficient to fund operations for at least the next 12 months under the current plan. The company completed corporate actions including Reverse Stock Splits (retroactively applied) and repurchased 2,455,702 shares for $2,565,511, leaving $2,434,489 available under its repurchase program. A legal/contract liability to Novartis resulted in current liabilities recorded as $3.6 million accounts payable, $1.4 million convertible promissory notes and accrued interest, and $0.4 million accrued liabilities. The company settled a prior SEC investigation by paying a $2.5 million civil penalty which was paid in cash on April 2, 2025.